Open Nav

Greenwich LifeSciences, Inc.

  • Snehal Patel, Greenwich LifeSciences

Raise capital for Phase III trial

  • Date:Thursday, October 18
  • Time:10:30 AM - 10:45 AM
  • Room:Elizabethan D
  • Location:2nd Floor
  • Session Type:Company Presentation
  • Presentation Type:Privately Funded Company
  • Company Description/Mission Statement:GP2 is a breast cancer immunotherapy that in a specific patient population is currently preventing cancer recurrences in the adjuvant setting. GP2 is a 9 amino acid Her2/neu transmembrane peptide delivered intradermally (with GMCSF) for the prevention of breast cancer recurrence following surgery (adjuvant setting) with a phase III clinical trial being planned for delivery of GP2-GMCSF in sequential combination with Herceptin to Her2/neu (3+) over expressor patients. A single blinded phase IIb clinical trial has completed enrollment of 180 patients of which 101 patients are Her2/neu (3+) over expressor patients. Efficacy data at greater than 4 year follow-up shows that there were no recurrences in the 51 Her2/neu (3+) patients treated with GP2-GMCSF-Herceptin, when fully vaccinated with the 6 primary injection series, versus a 12% recurrence rate in the 50 patient placebo arm treated with GMCSF-Herceptin (p < 0.05).
  • Company HQ City:Sugar Land
  • Company HQ Country:United States
  • Company HQ State:Texas                            
  • CEO/Top Company Official:Snehal Patel
  • Year Founded:2007
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development :GP2
  • Development Phase of Primary Product:Phase III
  • Previous and Current Investors:US Military, High net worth individuals
  • Total Amount Raised to Date, In All Rounds:$10m, including grants
Snehal Patel
Greenwich LifeSciences